Standout Papers

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma... 2015 2026 2018 2022 322
  1. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial (2015)
    Jean‐Charles Soria, Enriqueta Felip et al. The Lancet Oncology

Immediate Impact

1 by Nobel laureates 6 from Science/Nature 62 standout
Sub-graph 1 of 16

Citing Papers

Covalent targeted radioligands potentiate radionuclide therapy
2024 StandoutNature
Principles and therapeutic applications of adaptive immunity
2024 Standout
2 intermediate papers

Works of Young Joo Min being referenced

The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors
2019
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
2015 Standout

Author Peers

Author Last Decade Papers Cites
Young Joo Min 1377 1300 1001 105 2.7k
Jeri Kim 1179 1425 1240 100 3.2k
John Hilton 1201 601 816 159 2.6k
Dickran Kazandjian 1499 849 923 79 2.6k
Quincy S. Chu 2011 1531 1315 134 3.9k
Peter J. Van Veldhuizen 1385 1269 1383 96 3.5k
Douglas K. Price 1090 1002 1549 114 3.2k
Jeremy Braybrooke 1361 659 999 64 2.8k
Nancy A. Dawson 1309 2510 925 143 4.2k
Yan Sun 2282 2061 1050 107 4.0k
Takashi Kijima 1345 1178 1289 160 3.3k

All Works

Loading papers...

Rankless by CCL
2026